News archive
Showing 678 results
March 2020
-
Media ReleaseNovartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
-
Media ReleaseNovartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment- Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months(1)- Prespecified…
-
Media ReleaseNovartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapyInclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD…
-
Media ReleaseNovartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirementsConsumer Product Safety Commission-approved corrective action issued after Novartis identified that certain blister card packages of SANDIMMUNE® (cyclosporine capsules, USP) 100-mg soft gelatin…
-
StatementNovartis provides update on use and safety of Beovu® in patients with wet AMD
February 2020
-
Story Discovery
Shaping the future of sickle cell diseaseCollaborations are driving advances in sickle cell disease research, bringing new hope to patients.
-
StatementCorrective Action for Certain 100-mg SANDIMMUNE® and NEORAL® Blister Packages in the US
-
StatementNovartis launches new Preferred Firm Program for legal services
-
Media ReleaseNovartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review- FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)(1)-…
-
Media ReleaseNovartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
January 2020
-
Media ReleasePublic-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million PeopleHealthcare companies and philanthropies to fund training of thousands of community health workers as part of larger initiative led by Last Mile Health and Living Goods to advance universal health…
-
Media ReleasePublic-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People